Selenium status and blood lipids: the cardiovascular risk in young finns study
Version of Record online: 1 JUN 2011
© 2011 The Association for the Publication of the Journal of Internal Medicine
Journal of Internal Medicine
Volume 270, Issue 5, pages 469–477, November 2011
How to Cite
Stranges, S., Tabák, A. G., Guallar, E., Rayman, M. P., Akbaraly, T. N., Laclaustra, M., Alfthan, G., Mussalo-Rauhamaa, H., Viikari, J. S. A., Raitakari, O. T. and Kivimäki, M. (2011), Selenium status and blood lipids: the cardiovascular risk in young finns study. Journal of Internal Medicine, 270: 469–477. doi: 10.1111/j.1365-2796.2011.02398.x
- Issue online: 13 OCT 2011
- Version of Record online: 1 JUN 2011
- Accepted manuscript online: 9 MAY 2011 07:33PM EST
- risk factors;
Abstract. Stranges S, Tabák AG, Guallar E, Rayman MP, Akbaraly TN, Laclaustra M, Alfthan G, Mussalo-Rauhamaa H, Viikari JSA, Raitakari OT, Kivimäki M (Health Sciences Research Institute, University of Warwick Medical School, Coventry; University College London, London, UK; Semmelweis University Faculty of Medicine, Budapest, Hungary; Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA; National Center for Cardiovascular Research (CNIC), Madrid, Spain; University of Surrey, UK; National Institute of Health and Medical Research (Inserm) U888. F-34000 Montpellier, France; National Institute for Health and Welfare, Helsinki, Finland; Hjelt Institute, University of Helsinki, Helsinki; University of Turku and Turku University Hospital, Turku; University of Turku, Turku; Finnish Institute of Occupational Health and University of Helsinki, Helsinki, Finland). Selenium status and blood lipids: the cardiovascular risk in young finns study. J Intern Med 2011; 270: 469–477.
Background. Concern has been recently raised about possible adverse cardio-metabolic effects of high selenium status, such as increased risks of diabetes and hyperlipidaemia. However, most of the evidence comes from selenium-replete populations such as that of the United States.
Objectives. To examine cross-sectional and longitudinal associations of serum selenium with cardiovascular risk factors in Finland where selenium levels were amongst the lowest in the world until the early 1980s before the implementation of a nationwide selenium fertilization programme.
Methods. Serum selenium was measured in 1235 young Finns aged 3–18 years at baseline in 1980 (prefertilization) and in a subgroup (N = 262) at the 6-year follow-up (1986, postfertilization). During the 27-year follow-up, serum lipids, blood pressure, body mass index and smoking were assessed five times (1980, 1983, 1986, 2001 and 2007).
Results. Mean (±SD) serum selenium concentrations were 74.3 ± 14.0 ng mL−1 in 1980 and 106.6 ± 12.5 ng mL−1 in 1986 (average increase 32.3 ng mL−1; 95% CI: 30.3 to 34.3, P < 0.0001). In univariate and multivariable cross-sectional models in 1980 and 1986, increased serum selenium levels were consistently associated with increased total, HDL and Low-density lipoprotein (LDL) cholesterol. However, the average longitudinal changes in lipids were −0.20 mmol L−1 (95% CI: −0.30 to −0.10, P < 0.0001) for total cholesterol, 0.06 mmol L−1 (95% CI: 0.03 to 0.10, P < 0.0001) for HDL cholesterol, and −0.23 mmol L−1 (95% CI: −0.31 to −0.14, P < 0.0001) for LDL cholesterol. Selenium measured in 1986 was not associated with lipids assessed in 2001 and 2007.
Conclusions. Cross-sectional findings from the Young Finns study corroborate positive associations of selenium status with serum lipids. However, longitudinal evidence does not support the causality of this link.